

GENETIC TOXICOLOGY

Bacterial reverse mutation test - Ames test
OECD 471, ICH S2(R1)

The **Ames test** evaluates the mutagenic potential of chemicals assessing their genotoxic risk for human health or the environment.

The underlying principle of this test is the detection of mutations induced by the test substance that restore the tester strains functional capability. Therefore, the test substance is considered to be a mutagen if it causes an increase in the number of revertant colonies in any of the tester strains.

▶ **STUDY DURATION:**

- Approximately 7 weeks.

▶ **PRELIMINARY TESTS:**

- Sterility, solubility, cytotoxicity

▶ **STUDY TYPE:**

- 5 strains*

- With and without metabolic activation

* *S. typhimurium* (TA 98, TA100, TA1535, TA1537 and TA102) and/or *E. coli* (pKM101)





OUR MISSION

VectorB2B aims to enable the discovery and development of new therapies, by offering a range of comprehensive services and expertise to clients in the biotech, pharmaceutical, and academic sector. We earn our clients' trust by offering the best services, tailored to your specific needs.

WHY US?

We offer a low-risk “one-stop shop” for large- or small-scale projects, made possible by the depth of experience and the expertise of VectorB2B scientific team. VectorB2B will deliver high-quality custom or standard drug discovery solutions on time and budget.

CONTACT US

Our team is looking forward to meeting you and discussing the most efficient way to achieve your program goals



acustodio@vectorb2b.com



www.vectorb2b.com



VectorB2B-Drug Development



VECTOR ^{B2B}

DRIVING FORCE
in drug developing services